References
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1–636.
- European Center for Disease Prevention and Control. Factsheet about human papillomavirus; 2020 [cited 2020 Jul 1]. Available from: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet
- Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23;56(RR–2):1–24.
- Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018 Dec;17(12):1085–1091.
- Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016 Aug 15;63(4):519–527.
- Drolet M, Benard E, Perez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497–509.
- European Medicines Agency. Summary of product characteristics (EPAR): gardasil 9 2020; 2020 Nov [cited 2020 May 06]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9
- European Medicines Agency. Summary of product characteristics (EPAR): gardasil 2020; 2020 Nov [cited 2020 Mar 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil
- European Medicines Agency. Summary of product characteristics (EPAR): cervarix 2020; 2020 Nov [cited 2020 Jun 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix
- World Health Organization. Major milestone reached as 100 countries have introduced HPV vaccine into national schedule; 2019 [cited 2020 Jul 1]. Available from: https://www.who.int/news-room/detail/31-10-2019-major-milestone-reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule
- Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: the ESGO–EFC position paper of the European Society of Gynaecologic Oncology and the European Federation for Colposcopy. Eur J Cancer. 2019;116:21–26.
- European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries; 2008. Available from: https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0801_GUI_Introduction_of_HPV_Vaccines_in_EU.pdf
- European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update; 2012. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf
- European Center for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-on-HPV-vaccination-in-EU-countries2020-03-30.pdf
- Takla A, Wichmann O, Carrillo-Santisteve P, et al. Characteristics and practices of national immunisation technical advisory groups in Europe and potential for collaboration, April 2014. Euro Surveill. 2015 Mar 5;20(9):21049.
- Nohynek H, Wichmann O, D’Ancona F, et al. National advisory groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19(12):1096–1105.
- Dorleans F, Giambi C, Dematte L, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(47):19730.
- Poljak M, Seme K, Maver PJ, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013 Dec 31;31(Suppl 7):H59–70.
- Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul;4(7):e453–63.
- World Health Organization. European vaccine action plan 2015–2020. Copenhagen, Denmark: Regional Office for Europe; 2014. Available from: http://www.euro.who.int/__data/assets/pdf_file/0007/255679/WHO_EVAP_UK_v30_WEBx.pdf
- Nguyen-Huu NH, Thilly N, Derrough T, et al. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine. 2020 Feb 5;38(6):1315–1331.
- Elfstrom KM, Dillner J, Arnheim-Dahlstrom L. Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015 Mar 30;33(14):1673–1681.
- Lefevere E, Theeten H, Hens N, et al. From non school-based, co-payment to school-based, free Human Papillomavirus vaccination in Flanders (Belgium): a retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. Vaccine. 2015;33(39):5188–5195.
- Ferrer HB, Trotter C, Hickman M, et al. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014;14(1):700.
- Kessels SJ, Marshall HS, Watson M, et al. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012;30(24):3546–3556.
- Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction–the first five years. Vaccine. 2012 Nov 20;30(Suppl 5):F139–48.
- World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem; 2020.